- Home
- Products
- Customized ADCs
- CD200
- Anti-CD200 (Samalizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-CD200 (Samalizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-793)
This ADC product is comprised of an anti-CD200 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD200
- Alternative Names
- CD200; CD200 molecule; antigen identified by monoclonal MRC OX 2 , CD200 antigen , MOX1, MOX2; OX-2 membrane glycoprotein; MRC; OX 2; CD200 antigen; MRC OX-2 antigen; antigen identified by monoclonal MRC OX-2; MOX1; MOX2; OX-2;
- Target Entrez Gene ID
- 4345
- Target UniProt ID
- P41217
- Overview
- This gene encodes a type I membrane glycoprotein containing two extracellular immunoglobulin domains, a transmembrane and a cytoplasmic domain. This gene is expressed by various cell types, including B cells, a subset of T cells, thymocytes, endothelial cells, and neurons. The encoded protein plays an important role in immunosuppression and regulation of anti-tumor activity. Alternative splicing results in multiple transcript variants encoding different isoforms.
- Overview
- Humanized Anti-CD200 IgG2/G4-kappa antibody, Samalizumab
- Generic name
- Samalizumab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-APP (Gantenerumab)-SMCC-DM1 ADC (CAT#: ADC-W-680)
- Anti-CD3E (Foralumab)-SPDB-DM4 ADC (CAT#: ADC-W-837)
- Anti-ITGA4+ITGB7 (Crenezumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2503)
- Anti-ITGA4+ITGB7 (Abrilumab)-SPDB-DM4 ADC (CAT#: ADC-W-2385)
- Anti-IAV HA (Firivumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2467)
- Anti-MS4A1 (Ublituximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1559)
- Anti-IGF1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1237)
- Anti-CD79b (clone ch2F2)-SMCC-DM1 ADC (CAT#: ADC-W-168)
- Anti-C5 (Pexelizumab)-SPDB-DM4 ADC (CAT#: ADC-W-735)
- Anti-ERBB2 (Trastuzumab)-Mc-PEG8-Dol10 (Thiol Dol10) ADC (CAT#: ADC-W-389)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-793. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-790 | Anti-CD200 (Samalizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-788 | Anti-CD200 (Samalizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-791 | Anti-CD200 (Samalizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-789 | Anti-CD200 (Samalizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-792 | Anti-CD200 (Samalizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2564 | Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2542 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2576 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2570 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
